Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 10/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MITF | O75030 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6089749 | 0.93 | NR1I2 (0.49) | ALDH1A1PTPN1SOAT1NPC1RAB9A | |
| SCHEMBL6088907 | 0.89 | CDC25B (0.42) | ALDH1A1PTPN1APAF1SOAT1S100A4 | |
| SCHEMBL6088794 | 0.85 | PTPN1 (0.50) | ALDH1A1PTPN1SOAT1NPC1RAB9A | |
| SCHEMBL6090734 | 0.84 | CDC25B (0.50) | ALDH1A1APAF1SOAT1S100A4NPC1 | |
| SCHEMBL6089158 | 0.79 | ALDH1A1 (0.44) | ALDH1A1PTPN1APAF1SOAT1S100A4 | |
| Anthraquinone SCHEMBL27601272 | 0.75 | MEN1 (0.63) | ALDH1A1PTPN1APAF1SOAT1S100A4 | |
| Anthraquinone SCHEMBL27605254 | 0.73 | PTPN1 (0.61) | ALDH1A1PTPN1APAF1SOAT1S100A4 | |
| SCHEMBL6089567 | 0.73 | PTPN1 (0.49) | ALDH1A1PTPN1APAF1SOAT1S100A4 | |
| SCHEMBL11488767 | 0.73 | CASP3 (0.41) | ALDH1A1APAF1SOAT1S100A4NPC1 | |
| SCHEMBL598619 | 0.72 | NR1I2 (0.49) | ALDH1A1MAPTNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203230-A1 | Flame-retardant polyvinyl chloride compositions | TEKNOR APEX COMPANY | 2005-09-15 | — | — | US | claimed |
| US-20050019214-A1 | Colorable polymeric particles with biological probes | EASTMAN KODAK COMPANY | 2005-01-27 | — | — | US | claimed |
| WO-2004058865-A2 | FLAME-RETARDANT POLYVINYL CHLORIDE COMPOSITIONS | TEKNOR APEX COMPANY (US) | 2004-07-15 | — | — | WO | claimed |
| US-20040122149-A1 | Flame-retardant polyvinyl chloride compositions | TEKNOR APEX COMPANY | 2004-06-24 | — | — | US | claimed |
| US-6143484-A | ADDING TO EMULSION CONTAINING SILVER HALIDE PARTICLES SUFFICIENT AMOUNT OF SURFACTANT TO PASSIFY SURFACES OF SILVER HALIDE PARTICLES | EASTMAN KODAK COMPANY (US) | 2000-11-07 | — | — | US | claimed |
| WO-1999053860-A1 | bicycle seat | BONYF AG (LI) | 1999-10-28 | — | — | WO | claimed |
| EP-0169236-A1 | CONTROLLED RELEASE LIQUID DOSAGE FORMULATIONS FOR PHARMACEUTICALS | BATTELLE DEVELOPMENT CORPORATION (US) | 1986-01-29 | — | — | EP | claimed |
| US-4552751-A | Long-lasting multi-layered film preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 1985-11-12 | — | — | US | claimed |
| WO-1985003000-A1 | CONTROLLED RELEASE LIQUID DOSAGE FORMULATIONS FOR PHARMACEUTICALS | BATTELLE DEVELOPMENT CORPORATION (US) | 1985-07-18 | — | — | WO | claimed |
| EP-0050480-A2 | Long lasting multi-layered film preparation and process for its production | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-04-28 | — | — | EP | claimed |
| US-4222923-A | Adhesive composition and method of use | RHODES JOHN | 1980-09-16 | — | — | US | claimed |
| US-20240074968-A1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | SUNSHO PHARMACEUTICAL CO LTD (JP) | 2024-03-07 | — | — | US | disclosed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| WO-2023147443-A2 | NOVEL COMPOSITIONS | TULEX PHARMACEUTICALS INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146983-A1 | LIQUID RESIN EXTENDED-RELEASE ORAL NALTREXONE FORMULATION FOR TREATING AUTISM-RELATED DISORDERS | Aardvark Therapeutics, Inc. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-4076920-A | FREE RADICAL CATALYSTS | THE B. F. GOODRICH COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4011388-A | PROCESS FOR PREPARING EMULSIONS BY POLYMERIZATION OF AQUEOUS MONOMER-POLYMER DISPERSIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-03-08 | — | — | US | disclosed |
| US-4002702-A | BLENDING A DISPERSION RESIN WITH A NUCLEATING RESIN; SPRAY DRYING | STAUFFER CHEMICAL COMPANY (US) | 1977-01-11 | — | — | US | disclosed |
| US-3953386-A | Aqueous emulsions containing homogeneous particles of cellulosic ester/acrylic polymers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3936591-A | Nonmetallic-sheathed cable | THE ANACONDA COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALDH1A1 308/4885PTPN1 610/4885APAF1 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.